VivoSeq
Respiratory

LAM

0

Pipeline Programs↗

10

Active Trials↗

22

Companies Involved↗

LAM is an early-stage landscape with 0 programs across 22 companies. The most active players are GSK, Mylan Pharmaceuticals Inc, Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalMylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

PreclinicalTeva logo

Teva

0 programs

PreclinicalA

Alexza Pharmaceuticals, Inc.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

150

clinical trials

Completed117 · 78%
Unknown status12 · 8%
Recruiting8 · 5%
Withdrawn6 · 4%
Terminated5 · 3%
Active, not recruiting1 · 1%
Other1 · 1%

Clinical Trials

Trial Activity

150 trials

Personalized Therapies in Inflammatory Complex Disease
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03651518·32 enrolled
Dolutegravir Plus Lamivudine Simplified Therapy
Recruiting·GGuangzhou 8th People's Hospital·N/A·NCT03884673·300 enrolled
Anti-Inflammatory Reliever South Africa
Recruiting·UUniversity of KwaZulu·Phase 3·NCT06429475·1,038 enrolled
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Recruiting·WWashington University School of Medicine·Phase 1·NCT06538181·15 enrolled
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
Recruiting·UUniversity of Kiel·N/A·NCT06498349·60 enrolled
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
Recruiting·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT07242664·12 enrolled
Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA
Recruiting·UUniversity Health Network, Toronto·Phase 2/3·NCT05517434·148 enrolled
Specifying the Anti-inflammatory Effects of Ziltivekimab
Recruiting·—·Phase 3·NCT06263244·40 enrolled
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Active, not recruiting·Novartis logoNovartis·Phase 4·NCT05090371·136 enrolled
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Not yet recruiting·MMTI Biotech Inc·Phase 1/2·NCT06432166·48 enrolled
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets
Completed·GSK logoGSK·Phase 1·NCT01366547·18 enrolled
Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition
Completed·—·Phase 1·NCT01131949·26 enrolled
Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition
Completed·—·Phase 1·NCT01888731·62 enrolled
Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method
Completed·GGeropharm·N/A·NCT04501250·52 enrolled
The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry
Completed·MMaastricht University Medical Center·N/A·NCT00402207·33 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)